Modality
mRNA
MOA
EGFRi
Target
Aβ
Pathway
Innate Imm
WMNarcolepsy
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
Aug 2022
→ Feb 2031
Phase 2Current
NCT06435128
714 pts·WM
2022-08→2031-02·Recruiting
714 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-114.9y awayPh2 Data· WM
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Recruit…
Catalysts
Ph2 Data
2031-02-11 · 4.9y away
WM
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06435128 | Phase 2 | WM | Recruiting | 714 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |